To evaluate whether the urinary and serum. c-peptide is the indicator, of insulin therapy in NIDDM, and whether the insulin secretery capacity improves after control of blood glucose, We measured 24hour urinary c-peptide excretion, fasting and postprandial 2hour´s serum c-peptide concentrations before and after insulin therapy in 20 patients with NI-
DDM.
The results were as follows
1) The postprandial 2hour´s serum c-peptide level was significantly lower in patients with NIDDM than normal controls, but fasting serum c-peptide level and 24hour urinary c-peptide excretion showed no significant difference between normal control group and patients with NIDDM
2) There was no significant difference in duration of disease, body mass index, fasting serum c-peptide level and 24hour urinary c-peptide excretion between insulin-requiring group and non-insulin-requiring group among patients with NIDDM. But post prandial 2 hour´s serum c-peptide level was significantly lower in insulin requiring group than noninsulin-requiring group before treatment.
3) After therapy with insulin, post prandial 2hour´s serum c-peptide level increased significantly in insulin requiring group, but fasting serum c-peptide and 24hour urinary c-peptide excretion were not changed significantly after therapy with insulin comparing with the level before therapy.
Author concluded that postprandial 2hour´s serum c-peptide level was a marker of insulin therapy in patients with NIDDM and insulin secretory capacity improved after control-ling of blood glucose.
|